Get the Daily Brief
Latest Biotech News
Sanofi’s Amlitelimab Eczema Drug Meets Trial Endpoints but Disappoints Investors
Sanofi reported that its Phase 3 trial for amlitelimab, an anti-OX40L antibody for atopic dermatitis, successfully met primary and key secondary endpoints including skin clearance and disease...
FDA Delays Agios Pharmaceuticals’ Pyrukynd Decision Over Liver Safety Review
The FDA extended its decision deadline by three months for Agios Pharmaceuticals’ drug Pyrukynd, a treatment candidate for thalassemia, to allow for additional review of a liver safety mitigation...
Mercy BioAnalytics Raises $59 Million to Launch Early Cancer Detection Tests
Mercy BioAnalytics secured $59 million in Series B funding to commercialize its blood-based ovarian cancer screening test, targeting average-risk post-menopausal women and those with pelvic...
AC Immune Cuts Workforce, Prioritizes Parkinson’s and Neurodegenerative Programs
Swiss biotech AC Immune announced a 30% reduction in staff alongside a strategic pipeline downsizing, preserving cash runway extension of approximately six months. The company will deprioritize at...
BioMérieux Reports Modest 1% Revenue Growth Amid Product Mix Shifts
In Q2 2025, BioMérieux saw revenues rise 1% year-over-year to €945.9 million, driven by molecular biology clinical application gains offsetting weaknesses in immunoassays. Sales of molecular...
SeqOne Acquires Congenica, Enhances Clinical Interpretation for US Expansion
French genomics software firm SeqOne completed the acquisition of UK-based Congenica, gaining a CE-marked in vitro diagnostic clinical decision support platform and clinical interpretation...
Novartis Bets $200 Million on Arrowhead’s RNAi Therapy for Parkinson’s
Novartis has entered a global license and collaboration agreement with Arrowhead Pharmaceuticals, investing $200 million upfront to develop Arrowhead's preclinical siRNA therapy ARO-SNCA targeting...
Treeline Biosciences Unveils $1.1 Billion Pipeline with Three Cancer Drugs in Clinic
Treeline Biosciences emerged from stealth with a $200 million Series A extension, raising its total funding to over $1.1 billion. The Massachusetts-based biotech disclosed its lead cancer drug...
FDA Acceptance to Waive Clinical Efficacy Studies for Biosimilars
Professor Sarfaraz K. Niazi achieved a historic regulatory milestone with the FDA accepting the waiver of clinical efficacy studies (CESs) for monoclonal antibody biosimilars. This paradigm shift...
Ionis Pharmaceuticals Expands Lipid-Lowering Drug Use After Successful Trials
Ionis Pharmaceuticals reported positive Phase 3 results for Tryngolza in severe hypertriglyceridemia (sHTG), demonstrating significant reductions in triglyceride levels and pancreatitis prevention...
Merck’s Oral Cholesterol Drug Clears Another Late-Stage Hurdle
Merck’s experimental oral cholesterol medication has passed another Phase 3 clinical trial, advancing toward regulatory approval and expanding treatment options in a class largely dominated by...
FDA Grants Priority Review to Boehringer's Oral HER2-Selective TKI Zongertinib
The FDA approved Zongertinib (Hernexeos®, BI 1810631) in August 2025 for unresectable or metastatic non-squamous non-small cell lung cancer (nSCLC) harboring HER2 mutations, granting priority...
Mercy BioAnalytics Raises $59M to Launch Ovarian Cancer Screening Test
Mercy BioAnalytics completed a $59 million Series B funding round, accelerating commercialization of its blood-based ovarian cancer test targeting post-menopausal women and assisting diagnosis of...
Wave Life Sciences’ RNA Editing Therapy Shows Proof of Concept in AATD
Wave Life Sciences released updated results from its ongoing Phase Ib/IIa trial of WVE-006, an RNA editing oligonucleotide for alpha-1 antitrypsin deficiency (AATD). The data demonstrated durable...
Amgen Commits $600 Million to New Science and Innovation Center in California
Amgen announced a $600 million investment to construct a state-of-the-art Center for Science and Innovation at its Thousand Oaks global headquarters. The facility will consolidate...
Novartis and Arrowhead's $200 Million Parkinson’s RNAi Deal
Novartis has made a $200 million upfront investment to license Arrowhead Pharmaceuticals’ preclinical siRNA drug ARO-SNCA, targeting alpha-synuclein for Parkinson’s disease and other...
Mercy BioAnalytics Raises $59 Million to Launch Ovarian Cancer Screening Test
Mercy BioAnalytics secured $59 million in Series B funding to support the commercialization of its blood-based ovarian cancer screening tests set for initial rollout in 2026. The company's Halo...
Wave Life Sciences’ RNA Editing Therapy Shows Durable Activity but Investor Response Mixed
Wave Life Sciences released updated Phase Ib/IIa clinical data for its RNA editing oligonucleotide WVE-006 targeting alpha-1 antitrypsin deficiency (AATD). The results confirmed sustained...
Treeline Biosciences Surfaces With $1.1 Billion Raised and Three Cancer Drugs in Clinic
Treeline Biosciences, under the leadership of veteran drug hunters Josh Bilenker and Jeff Engelman, emerged from stealth announcing three oncology drug candidates entering clinical trials and a...
Ionis Pharmaceuticals’ Lipid-Lowering Drug Hits Phase 3 Goals, Plans Label Expansion
Ionis Pharmaceuticals announced that its antisense oligonucleotide drug Tryngolza met primary and secondary endpoints in two Phase 3 trials (Core and Core2) targeting severe hypertriglyceridemia....